Kechow Pharma

Chinese, early stage biotech developing MEK inhibitors for Lung and colorectal cancers.

placeShanghai, Shanghai, China calendar_todayFounded 2014 groups80 employees language kechowpharma.com

Innovation

16 patent families (1 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 108 times.

YearFilings
20142
20151
20163
20181
20211
20223
20232
20242
20253

Investor mix

11 investors on record; lead investors include Decheng Capital.

Investor typeCountShare
Venture capital873%
Private equity218%
Other / undisclosed19%
Coming soon